Immix Biopharma Inc (IMMX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$13.91+0.58%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · IMMX
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -30.4% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name operates in a high-miss-rate industry and has been missing across recent quarters. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
IMMX — debt issuance
Dated 2026-05-21
Other Events. On May 21, 2026, Immix Biopharma, Inc., a Delaware corporation (the “Company”), entered into an underwriting agreement (the “Underwriting Agreement”) with Morgan Stanley & Co. LLC, as representative of the several underwriters named in Schedule I thereto, pursuant to which the Company agreed to issue and sell, in an underwritten offering (the “Offering”), an aggregate of 16,778,524 shares of its common stock, par value $0.0001 per share (the “Shares”) at a public offering price…
Why it matters: If healthcare sector revenue growth speeds up, it may help Immix Biopharma.
Supportive ifHealthcare sector revenue growth speeds up to 10% or more.
Worry ifHealthcare sector revenue growth keeps slowing down below current levels.
Why it matters: This report will provide insights into financial health and cash burn trends. It is crucial for assessing operational stability.
Watch forThe earnings report shows less cash burn. It also shows better financial numbers than Q1 2026.
Also watch forThe earnings report shows more cash burn. It also shows worse financial numbers than Q1 2026.
Why it matters: Litigation outcomes can affect the company’s reputation and financial health. This is a risk to monitor.
Watch forA settlement or good news comes out about the lawsuit.
Also watch forA bad ruling or more legal issues is reported.
Why it matters: Management wants to reduce cash burn. This shows better cost control and efficiency.
Supportive ifOperating losses decrease from -$12.5M in Q2 2026 to less than -$10M in Q3 2026.
Worry ifOperating losses worsen beyond -$12.5M in Q3 2026.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$264 on $10,000 · ±2.6% | How much price usually moves either way. |
| Bad day | $673 loss on $10,000 · 6.7% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $3,984 loss on $10,000 · 39.8% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Finishing this will give money needed for NXC-201 development. Not finishing could hurt operations.
Supportive ifThe company finishes the offering and gets $150 million in gross proceeds.
Worry ifThe offering fails to close or raises significantly less than $150 million.
Why it matters: This update will show if the high complete response rate continues. It is key for future trials and potential approval.
Supportive ifThe NEXICART-2 update shows a complete response rate above 95% for at least 25 patients.
Worry ifThe update shows a complete response rate dropping below 90% or no new data is presented.
Why it matters: A timely BLA submission is crucial for the commercial launch of NXC-201. Delays could impact investor confidence.
Supportive ifThe company submits the BLA by the end of March 2027 as planned.
Worry ifThe company delays the BLA submission beyond March 2027.
Why it matters: High cash burn may show financial problems. Investors want to know if the company can control costs.
Worry ifQ3 cash burn decreases from the $11.7M in Q2 2026.
Less concerning ifQ3 cash burn increases beyond $11.7M.